Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrataXRT for Radiation Dermatitis in Breast and Head and Neck Cancer
NCT05073172Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial in radiation-induced dermatitis (RID) comparing StrataXRT with Standard of Care (2 arms). Primary endpoint: Radiation dermatitis incidence and severity. Planned start Jan 2024; status: withdrawn.
02
Drugs
StrataXRT
03
Conditions
radiation-induced dermatitis (RID)
Beyond the preview
Go deeper on NCT05073172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05073172.